Immune Defense Protein Impact On Respiratory Immune Outcomes

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection

In brief

The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season. Secondary aims include observing the product's effect on rescue medication use, quality of life, and overall tolerability. This is conducted as a consumer-driven, decentralized observational clinical research study in adults aged 60 or older, using self-reported measures and questionnaires completed at home via the Chloe App.

Key facts

Study ID

NCT07431840

Run by

Quantec Ltd

People needed

300

Starts

2025-12-05

Expected to finish

2026-07-31

Last updated by the study team

2026-03-12

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 60 years and older
• Individuals who experience upper respiratory symptoms (e.g. coughing, sneezing, congestion) at least 2-3 times during the cold/flu season.
• Able to read and understand English.
• Able to read, understand, and provide informed consent.
• Able to use a personal smartphone device and download Chloe by People Science.
• Able to receive shipment of the product at an address within the United States.

You may not qualify if…

• Any potential participants who:
• Do not have a personal smartphone, internet access, or unwilling to download Chloe.
• Already in an immunocompromised state, including:
• A. Infectious Causes
• HIV/AIDS
• Chronic hepatitis B or C (advanced stages)
• Tuberculosis (especially disseminated or extrapulmonary TB) B. Cancer-Related
• Leukemia (e.g., AML, ALL, CLL)
• Lymphoma (e.g., Hodgkin's and Non-Hodgkin's)
• Multiple Myeloma
• Any metastatic cancer receiving chemotherapy
• C. Immunosuppressive Therapy:
• Participants on:
• Corticosteroids (e.g., ≥20 mg/day of prednisone for ≥2 weeks)
• Biologics (e.g., TNF inhibitors like infliximab, adalimumab)
• Calcineurin inhibitors (e.g., tacrolimus, cyclosporine)
• mTOR inhibitors (e.g., sirolimus)
• JAK inhibitors (e.g., tofacitinib)
• Chemotherapy or radiation therapy
• Anti-rejection meds post-organ transplant D. Transplant Patients
• Solid organ transplant (kidney, liver, heart, lung)
• Hematopoietic stem cell transplant (HSCT) E. Autoimmune or Inflammatory Diseases (especially when treated with immunosuppressants)
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus (SLE)
• Psoriasis or Psoriatic Arthritis

Where it is running

• People Science, Inc. — Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.